Theravance Biopharma Statistics
Total Valuation
TBPH has a market cap or net worth of $481.66 million. The enterprise value is $443.89 million.
Important Dates
The last earnings date was Tuesday, November 12, 2024, after market close.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TBPH has 49.17 million shares outstanding. The number of shares has decreased by -18.30% in one year.
| Current Share Class | 49.17M |
| Shares Outstanding | 49.17M |
| Shares Change (YoY) | -18.30% |
| Shares Change (QoQ) | +0.60% |
| Owned by Insiders (%) | 7.98% |
| Owned by Institutions (%) | 44.60% |
| Float | 21.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 37.14 |
| PS Ratio | 7.71 |
| Forward PS | 17.52 |
| PB Ratio | 2.64 |
| P/TBV Ratio | 2.57 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.02 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.97, with a Debt / Equity ratio of 0.24.
| Current Ratio | 4.97 |
| Quick Ratio | 4.62 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.63 |
Financial Efficiency
Return on equity (ROE) is -22.88% and return on invested capital (ROIC) is -9.35%.
| Return on Equity (ROE) | -22.88% |
| Return on Assets (ROA) | -6.41% |
| Return on Capital (ROIC) | -9.35% |
| Revenue Per Employee | $638,303 |
| Profits Per Employee | -$499,000 |
| Employee Count | 99 |
| Asset Turnover | 0.16 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, TBPH has paid $8.71 million in taxes.
| Income Tax | 8.71M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -4.59% in the last 52 weeks. The beta is 0.25, so TBPH's price volatility has been lower than the market average.
| Beta (5Y) | 0.25 |
| 52-Week Price Change | -4.59% |
| 50-Day Moving Average | 8.52 |
| 200-Day Moving Average | 8.81 |
| Relative Strength Index (RSI) | 72.74 |
| Average Volume (20 Days) | 197,197 |
Short Selling Information
The latest short interest is 4.92 million, so 10.01% of the outstanding shares have been sold short.
| Short Interest | 4.92M |
| Short Previous Month | 5.04M |
| Short % of Shares Out | 10.01% |
| Short % of Float | 23.41% |
| Short Ratio (days to cover) | 31.50 |
Income Statement
In the last 12 months, TBPH had revenue of $63.19 million and -$49.40 million in losses. Loss per share was -$1.01.
| Revenue | 63.19M |
| Gross Profit | 26.69M |
| Operating Income | -39.48M |
| Pretax Income | -38.22M |
| Net Income | -49.40M |
| EBITDA | -39.69M |
| EBIT | -39.48M |
| Loss Per Share | -$1.01 |
Full Income StatementBalance Sheet
The company has $91.36 million in cash and $44.98 million in debt, giving a net cash position of $46.38 million or $0.94 per share.
| Cash & Cash Equivalents | 91.36M |
| Total Debt | 44.98M |
| Net Cash | 46.38M |
| Net Cash Per Share | $0.94 |
| Equity (Book Value) | 185.65M |
| Book Value Per Share | 3.78 |
| Working Capital | 93.05M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$11.49 million and capital expenditures -$819,000, giving a free cash flow of -$12.31 million.
| Operating Cash Flow | -11.49M |
| Capital Expenditures | -819,000 |
| Free Cash Flow | -12.31M |
| FCF Per Share | -$0.25 |
Full Cash Flow StatementMargins
Gross margin is 42.23%, with operating and profit margins of -62.47% and -78.18%.
| Gross Margin | 42.23% |
| Operating Margin | -62.47% |
| Pretax Margin | -64.39% |
| Profit Margin | -78.18% |
| EBITDA Margin | -62.81% |
| EBIT Margin | -62.47% |
| FCF Margin | -15.48% |
Dividends & Yields
TBPH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 18.30% |
| Shareholder Yield | 18.30% |
| Earnings Yield | -10.35% |
| FCF Yield | -2.58% |
Analyst Forecast
The average price target for TBPH is $13.75, which is 40.38% higher than the current price. The consensus rating is "Buy".
| Price Target | $13.75 |
| Price Target Difference | 40.38% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 30.67% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TBPH has an Altman Z-Score of -2 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2 |
| Piotroski F-Score | 3 |